CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenue:
Net product sales	$ 519,205	$ 148,886
Consulting research & development income	63,192	9,696
Shipping and other sales	1,544	21,822
Total revenues	583,941	180,404
Cost of goods sold:
Cost of goods sold	279,924	180,629
Gross profit (loss)	304,017	(225)
Operating expenses:
Research and development expenses	1,408,595	1,427,341
Selling, general and administrative expenses	6,453,113	5,914,541
Total operating expenses	7,861,708	7,341,882
Net Operating (loss) before other income (expense)	(7,557,691)	(7,342,107)
Other income (expense):
Interest income		6
Other income	577,370	34,412
Loss on disposal of property, plant & equipment		(12,351)
Change in fair value of derivative liability	(229,291)	742,109
Other expense	(183,962)	(3,580)
Interest expense	(3,037,299)	(1,582,184)
Other income (expense)	(2,873,182)	(821,588)
Net loss before income taxes	(10,430,873)	(8,163,695)
Provision for income taxes
Net loss	(10,430,873)	(8,163,695)
Net loss attributable to non-controlling interest	(30,472)	(13,810)
Net loss attributable to Cure Pharmaceutical Holding Corp.	$ (10,400,401)	$ (8,149,885)
Net loss per share
Basic and Diluted	$ (0.42)	$ (0.34)
Weighted average common shares outstanding
Basic and Diluted	24,999,824	23,649,432